Background: Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB). Due to its direct mechanism of action, sugammadex is associated with rapid and predictable reversal of deep NMB. The current analysis compares the clinical efficacy and risk of postoperative nausea and vomiting (PONV) on using sugammadex or neostigmine for routine NMB reversal in adult and pediatric populations.
Methods: PubMed and ScienceDirect were searched as the primary databases. Randomized controlled trials comparing sugammadex with neostigmine for routine NMB reversal in adult and pediatric patients have been included. The primary efficacy endpoint was the time from initiation of sugammadex or neostigmine to the recovery of a time-of-four ratio (TOF) ≥ 0.9. PONV events have been reported as secondary outcomes.
Results: A total of 26 studies have been included in this meta-analysis, 19 for adults with 1574 patients and 7 for children with 410 patients. Sugammadex, when compared to neostigmine, has been reported to take a shorter time to reverse NMB in adults (mean difference = -14.16 min; 95% CI [-16.88, -11.43], < 0.01), as well as in children (mean difference = -26.36 min; 95% CI [- 40.16, -12.57], < 0.01). Events of PONV have been found to be similar in both the groups in adults, but significantly lower in children treated with sugammadex,, 7 out of 145 with sugammadex versus 35 out of 145 with neostigmine (odds ratio = 0.17; 95% CI [0.07, 0.40]).
Conclusion: Sugammadex is associated with a significantly shorter period of reversal from NMB in comparison to neostigmine in adult and pediatric patients. Regarding PONV, the use of sugammadex for NMB antagonism may offer a better option for pediatric patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574886318666230302124634 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Liver Disease on Use of Muscle Relaxants in Anesthesia: A Comprehensive Review.
Med Sci Monit
January 2025
Department of Nephrology, Transplantology and Internal Diseases, Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland.
Article Synopsis
- Skeletal muscle relaxants are commonly used in anesthesia for surgeries, mechanical ventilation, and intubation, creating a conduction block at the neuromuscular junction.
- Reversal agents, like neostigmine and sugammadex, help terminate the neuromuscular blockade and prevent residual effects, but their efficacy can be affected by liver and kidney dysfunction.
- Liver damage, which can stem from various causes including drug toxicity and metabolic disorders, impairs drug metabolism and can lead to systemic complications, ultimately impacting the use of muscle relaxants in patients with liver disease.
Sugammadex versus Neostigmine in Renal Impairment.
Anesth Analg
December 2024
Concord Repatriation General Hospital, Concord, New South Wales, Australia,
Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study.
Anesth Analg
January 2025
From the Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Background: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing.
View Article and Find Full Text PDFNeuromuscular Blockade Reversal with Sugammadex Reduces Cardiac Complications and OR Time for Prone Lumbar Spinal Fusion Compared to Neostigmine.
Spine (Phila Pa 1976)
December 2024
Brown University Department of Orthopaedic Surgery, Providence, Rhode Island.
Study Design: Retrospective cohort study.
Objective: To evaluate inpatient complication profiles of patients receiving neuromuscular blockade reversal via sugammadex versus neostigmine/glycopyrrolate.
Summary Of Background Data: Sugammadex is a neuromuscular blockade reversal agent that binds non-depolarizing muscle relaxants.
A Review of Muscle Relaxants in Anesthesia in Patients with Neuromuscular Disorders Including Guillain-Barré Syndrome, Myasthenia Gravis, Duchenne Muscular Dystrophy, Charcot-Marie-Tooth Disease, and Inflammatory Myopathies.
Med Sci Monit
December 2024
Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Anesthesia management in neuromuscular diseases (NMDs) is a complex challenge, requiring careful preoperative evaluation, tailored treatment strategies, and vigilant perioperative monitoring. This review examines the nuances of anesthesia in patients with NMD, addressing potential complications such as intubation difficulties, respiratory failure, and adverse effects of anesthetics and neuromuscular conduction blocking agents (NMBAs). Nondepolarizing NMBAs, including steroidal agents and benzylisoquinolines, are analyzed for their role, risks, and optimal use based on procedural requirements and patient characteristics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!